Patients with a COPD flare and blood eosinophils of >300 cells/µl in the prior year received mepolizumab or placebo for 48 weeks, plus exacerbation treatment. The median time to hospitalization or death due to any cause was similar in both groups.
eviden.cc/42YLiQt